CPA
COGT icon

Capital Performance Advisors’s Cogent Biosciences COGT Stock Holding History

Capital Performance Advisors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-37
Closed -$400 – 698
2024
Q3 		$400 Buy
+37
New +$360 ﹤0.01% 2350

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Capital Performance Advisors's COGT Position: Q4 2024 in Review

Capital Performance Advisors sold out of Cogent Biosciences (COGT) in Q4 2024, closing a stake of 37 shares — an estimated $400 sold.

Capital Performance Advisors first reported a position in COGT in Q3 2024 and held it in 1 quarter. The position peaked at $400 in Q3 2024. 176 funds tracked by Wall St. Rank hold COGT as of Q4 2024.

  • Capital Performance Advisors reported no remaining Cogent Biosciences position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 37 Cogent Biosciences shares in Q4 2024, an estimated $400.
  • Capital Performance Advisors first reported a position in Cogent Biosciences in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Cogent Biosciences position peaked at $400 in Q3 2024.
  • 176 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.